NCT03102606 2024-08-29
Protective-1
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
Clinical Trials
7 trialsNCT04345900 2024-05-16
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT02504489 2022-09-10
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT04227990 2020-01-18
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT00630110 2011-08-16
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Nereus Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00322608 2011-01-10
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Nereus Pharmaceuticals, Inc.
Phase 1 Completed